Mycotopia is researching and developing psychedelic therapies for mental disorders including; anxiety, depression, bipolar disorders, PTSD, ADHD, autism and addictions.
Mycotopica
The company intends to enter the medical tourism market and offer a number of psychedelic retreats in various locations across the globe. At present, there is limited information available regarding the exact psychedelics Mycotopia are working with.
In March 2021, Mycotopia announced the formation of PsyBioMed in partnership with Australian psychedelic research and development company Natural MedTech. PsyBioMed plan to build an R&D laboratory and manufacturing facility in Victoria, Australia.
A former subsidiary of Ehave, Mycotopia was sold to 20/20 Global Inc in December 2020. By maintaining their relationship with Ehave, Mycoptopia have access to digital therapeutic blockchain technology that allows for the secure and compliant capture of in-depth data sets. This data can be used to help clinically validate some forms of therapy the company are working on and enhance patient access to their own data.
News
- Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In Psychedelics (Globe Newswire, March 2021).
- Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value (Globe Newswire, December 2020).
Activities
B2B
B2C
Biotech
Retreat
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction (GlobeNewswire, 19 May 2022)Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression (TPIA) (, 17 November 2021)
Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures (Yahoo Finance, 08 December 2021)
Mycotopia and Ei.Ventures announced the signing of an LOI to explore a merger and the formation of PSLY.COM, a $360 Million transaction, and will apply to list shares on NASDAQ; Ehave plans to spin out 30%.